Jan Medical’s Nautical BrainPulse™ Detected Cerebral Vasospasm with Clinically Meaningful Accuracy in UCSF Study Published in Neurocritical Care

”Detection of cerebral vasospasm is currently problematic.
If it is detected prior to development of cerebral ischemia,
morbidity can be reduced, or eliminated. What we need is a
safe, noninvasive, user-independent method to detect
cerebral vasospasm before it causes brain injury.”

Wade S. Smith, MD, PhD
Professor and Vice-Chair
Chief, UCSF Neurovascular Division
Department of Neurology
University of California, San Francisco (UCSF)

MOUNTAIN VIEW, Calif.--()--Jan Medical, developer of the Nautilus BrainPulse™, announced today that a clinical study published in this month’s issue of Neurocritical Care demonstrated that Nautilus BrainPulse is a highly sensitive skull accelerometry that can detect cerebral vasospasm “with clinically meaningful accuracy, therefore suggesting “promise in the ICU environment to detect as well as reject cerebral vasospasm as the cause of neurological deficits in subarachnoid hemorrhage.”

“Cranial Accelerometry Can Detect Cerebral Vasospasm Caused by Subarachnoid Hemorrhage”

Prinicipal investigator for the Nautilus BrainPulse study was Wade S. Smith, M.D., Ph.D., Director, UCSF Neuroscience ICU, Professor of Neurology, University of California, San Francisco.

“What we need is a safe, noninvasive, user-independent method to detect cerebral vasospasm before it causes brain injury,” said Dr. Smith. “The technology needs to be simple, and portable, to be most effective in the Neuro Critical Care setting, by more immediately detecting vasospasm so we can aggressively prevent stroke with cerebral angioplasty and/or vasospressor therapy. Such a technology holds the promise to directly help patients and shorten the length of stay within the Neuro ICU.”

“Our Nautilus BrainPulseTM system can rapidly provide critical information on a patient presenting with stroke symptoms, and it can also be used as a continuous monitor of changes to the cerebral vasculature. It is this latter ability, continuous monitoring, that provides a unique capability in detecting the onset of vasospasm,” added Paul Lovoi, Ph.D., CEO of Jan Medical. “This study has confirmed that our portable and continuous brain-sensing system can detect vasospasms quickly and noninvasively.”

“Vasospasm” refers to a condition in which blood vessels constrict, leading to ischemia and irreversible brain injury by causing stroke. Cerebral vasospasm usually arises in the context of subarachnoid hemorrhage (SAH) from a ruptured cerebral aneurysm. Vasospasm typically materializes 4 to 10 days after SAH. The essential problem with vasospasm is that it causes stroke by shutting down blood flow to the brain. The current method used to detect vasospasm is transcranial Doppler ultrasound, a difficult to administer technique that is not able to evaluate all the brain’s blood vessels and requires specific technical expertise to perform the measurements.

The brain has a normal pulse driven by the cardiac cycle. The impact of this pulse on the skull can in turn be detected and measured. The Nautilus BrainPulse is designed to measure the normal brain pulse as well as disruptions of the brain pulse. By digitizing the signal patterns from headset-mounted sensors measuring the skull’s motion, and extracting features from them, algorithms have been developed to identify normal and a variety of abnormal brain pulse patterns in recording sessions that take approximately 3 minutes. The device is portable, entirely non-invasive and provides analysis immediately once the recording session is completed.

About Jan Medical

Jan Medical is medical device company dedicated to providing critical data for expediting and expanding therapy while improving the diagnostic experience for patients with brain disorders. Its proprietary platform technologies include the Nautilus BrainPulse™. Visit www.janmedical.com.



Ronald Trahan Associates
Ronald Trahan, 508-359-4005

Release Summary

Jan Medical’s Nautical BrainPulse™ detected cerebral vasospasm with clinically meaningful accuracy in UCSF study published in Neurocritical Care


Ronald Trahan Associates
Ronald Trahan, 508-359-4005